Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa).

Authors:

Abstract
5065 Background: Tumor mutational load and neoantigens have been associated with responses to immune checkpoint therapies in patients (pts) with melanoma and lung cancer. We designed a clinical trial (NCT02113657) in advanced PCa to determine whether the induction of antitumor responses by IPI correlate with T cell responses to PCa neoantigens. Methods: All advanced PCa pts enrolled into this study had sufficient DNA/RNA from tumor tissue obtained prior to receiving IPI (3 mg/kg every 21 days for up to 4 doses) for whole-exosome sequencing (WES) and RNA-seq. Results: Twenty-one of 30 pts have been enrolled. Nine (43%) have received all 4 doses of IPI. IPI was discontinued prematurely in 9 pts (43%) due to drug-related toxicities and in 3 (14%) due to disease progression. All 3 of the latter had liver metastases. To date, tumors from 13 pts have been comprehensively analyzed by WES and RNA-seq. The median time from IPI #1 to the next systemic therapy for these pts was 24 weeks (IQR, 18.3 – 54.3). Responders (R) were defined as pts whose time to next systemic therapy was > 24 weeks. The median time to next systemic therapy for R (n = 7, 54%) is 55 weeks (IQR, 52.0 – 89.0; 2 pts with ongoing responses) versus 18 weeks (IQR, 10.5 – 23.0) for non-responders (NR; n = 6, 46%). In an analysis of all 13 pts, including those with liver metastases, tumor mutational load and frequency of expressed non-synonymous mutations were similar for R and NR pts. However, a subset analysis, excluding pts with liver metastases, revealed > 100 total mutations and/or > 10 expressed non-synonymous mutations in 7/7 R versus 1/4 NR. Conclusions: For advanced PCa pts without liver metastases, tumor mutational load may be associated with responses to IPI. Identification of immunodominant neoantigens may lead to the development of personalized vaccines to be combined with immune checkpoint therapies for the effective treatment of pts with PCa. Clinical trial information: NCT02113657.